May 7, 2024

Health Canada approves ZOLADEX® LA for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women.

> Learn More

February 20, 2017

AstraZeneca announced today that it has entered into an agreement with TerSera Therapeutics LLC (“TerSera”) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. This transaction is expected to close during Q1 of 2017.